New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Journey

PharmaEssentia to Host Investor Day in New York City on November 30, 2022

Presentations on Ropeginterferon Alfa-2b During ASH Annual Meeting Highlight Momentum in the Care of Polycythemia Vera (PV)

PharmaEssentia Corporation Announces Closing of Follow-on Public Offering, Generating More Than 200M USD to Support Growth Ambitions

PharmaEssentia USA Expands Leadership with Executive Hires in Marketing, Medical Affairs and Communications and Advocacy

PharmaEssentia Defines a Growth-Oriented Discovery and Development Strategy with Newly Appointed CSO Dr. Lih-Ling Lin at the Helm

Review of SURPASS-ET Trial Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia (ET) Published in Future Oncology

PharmaEssentia Appoints Dr. Lih-Ling Lin as Chief Scientific Officer

PharmaEssentia Honored at the National Organization of Rare Disorders (NORD(R)) 2022 Rare Impact Awards for the Introduction of BESREMi(R) (ropeginterferon alfa-2b) for Polycythemia Vera

New Data on Ropeginterferon Alfa-2b to be Featured at EHA2022